Agenus is adding to its capabilities in checkpoint inhibitors with the licensing of antibody programs from Italy's Diatheva.
The Massachusetts biotech announced 20 July that it has gotten the worldwide development and commercialization rights to Diatheva's CEACAM1 (carcinoembryonic...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

